Lineage Cell Therapeutics (LCTX) Interest Coverage Ratio (2010 - 2026)

Lineage Cell Therapeutics' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 0.65 for Q1 2026.

• On a quarterly basis, Interest Coverage Ratio rose 96.97% year-over-year to 0.65 in Q1 2026; TTM through Mar 2026 was 3.21, a 123.63% decrease from a year earlier, with the FY2025 full-year figure at 0.41, down 64.58% from the prior year.
• Interest Coverage Ratio declined to 0.65 in Q1 2026 per LCTX's latest filing, from 9.01 in the prior quarter.
• Across five years, Interest Coverage Ratio topped out at 12.6 in Q4 2022 and bottomed at 84.68 in Q2 2022.
• The 5-year median for Interest Coverage Ratio is 7.18 (2025), against an average of 11.19.
• Across the five-year window, Interest Coverage Ratio soared 111.06% in 2022 and plunged 698.55% in 2025, its largest moves.
• Year by year, Interest Coverage Ratio stood at 12.6 in 2022, then fell by 20.22% to 10.05 in 2023, then decreased by 28.69% to 7.17 in 2024, then gained by 25.67% to 9.01 in 2025, then tumbled by 107.18% to 0.65 in 2026.
• Per Business Quant, the three latest LCTX Interest Coverage Ratio figures stand at 0.65 (Q1 2026), 9.01 (Q4 2025), and 0.25 (Q3 2025).